Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

The biotech company said it anticipates between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...

Moderna led S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S. The biotech company is developing a vaccine for H5N1.

Moderna is still generating decent sales from its COVID-19 vaccine. The biotech has won important clinical and regulatory approvals this year. Moderna's portfolio should look much stronger in a ...

In the third quarter, Moderna reported $1.9 billion in revenue, roughly flat compared to the year-ago period. On the bottom line, the biotech reported net earnings per share of $0.03 compared to a ...